Enveric Biosciences (ENVB) Preferred Dividend Payments (2017 - 2025)
Enveric Biosciences (ENVB) posted Preferred Dividend Payments of $1.8 million for Q4 2025, up 21.98% sequentially from $1.5 million in Q3 2025.
Enveric Biosciences (ENVB) Preferred Dividend Payments (2017 - 2025) Analysis & Trends
Enveric Biosciences has reported Preferred Dividend Payments for 7 years, with the latest figure at $1.8 million in Q4 2025.
- Quarterly Preferred Dividend Payments changed N/A year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.4 million (changed N/A YoY) and the FY2025 annual result came in at $3.4 million, changed N/A from the prior year.
- Preferred Dividend Payments rose to $1.8 million in Q4 2025 per ENVB's latest filing, from $1.5 million in the prior quarter.
- Over five years, Preferred Dividend Payments peaked at $1.8 million in Q4 2025 and troughed at -$151971.0 in Q4 2022.
- A 3-year average of $477633.9 and a median of $36997.0 in 2023 frame the typical range for Preferred Dividend Payments.
- The widest YoY moves for Preferred Dividend Payments: up 50.0% in 2023, down 50.0% in 2023.
- Over 3 years, Preferred Dividend Payments stood at -$151971.0 in 2022, then soared by 124.34% to $36997.0 in 2023, then jumped by 4889.69% to $1.8 million in 2025.
- According to Business Quant data, Preferred Dividend Payments over the past three periods registered $1.8 million, $1.5 million, and $36997.0 for Q4 2025, Q3 2025, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | - |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | - |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | Enveric Biosciences | 5.42 Mn | -2.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.85 Mn |
| Sep 30, 2025 | 1.51 Mn |
| Jun 30, 2023 | 36,997.00 |
| Mar 31, 2023 | 12,329.00 |
| Dec 31, 2022 | -151,971.00 |
| Sep 30, 2022 | 12,603.00 |
| Jun 30, 2022 | 73,994.00 |
| Sep 30, 2020 | 109,457.00 |
| Jun 30, 2020 | 107,835.00 |
| Mar 31, 2020 | 107,835.00 |
| Dec 31, 2019 | 107,299.00 |
| Sep 30, 2019 | 106,765.00 |
| Jun 30, 2019 | 106,234.00 |
| Mar 31, 2019 | 105,705.00 |
| Dec 31, 2018 | 105,180.00 |
| Sep 30, 2018 | 1.82 Mn |
| Jun 30, 2018 | 104,136.00 |
| Mar 31, 2018 | 557,417.00 |
| Dec 31, 2017 | 542,496.00 |
| Sep 30, 2017 | 541,864.00 |